Toxicity to intravitreal melphalan in a patient with retinoblastoma.

Autores de IIS La Fe

• Honorio Barranco González

  Autor

• Isabel Pascual Camps

  Autor

• Enrique España Gregori

  Autor

Participantes ajenos a IIS La Fe

• Solaz-Ruiz, Marta Gema
• Perez, Lorena Azorin
• Cauto-Picazo, Carlos

Grupos

• Investigación en Neuroinmunología y Esclerosis Múltiple

• Perinatología

Abstract

Objective: Description of melphalan's toxicity in retinoblastoma treatment. Methods: Clinical case report. Results: We presented a case of unilateral retinoblastoma with vitreous seeding at diagnosis, in which the use of intravitreal melphalan produced many adverse reactions. Conclusions: Vitreous seedings have been one of the most important challenges in retinoblastoma treatment. Intravitreal melphalan has achieved the regression of vitreous seedings in a large percentage of cases. It is a safe treatment; however, it can produce toxicity, even with the standard dose of 20-30 g, which has been poorly documented. Exhaustive follow-up of patients is recommended for an early diagnosis of possible adverse effects. Abbreviations: OS = left eye, RI = magnetic resonance imaging, OCT = optical coherence tomography.

#x00A9; The Authors.Romanian Society of Ophthalmology.

Keywords

• hypotonia; intravitreal melphalan; ocular toxicity; phthisis bulbi; retinoblastoma